Astec LifeSciences liquidity ratios

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

2.41×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
0.89×	0.89×	0.93×	1.00×	0.95×
0.61×	0.61×	0.50×	0.51×	0.39×
0.1	10.0	0.6	0.5	0.5
−112	−56.8	−24.6	1.3	−27.3

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ASTEC₹581.05

Astec LifeSciences Limited

· Chemicals

₹ CrorePeersPUNJABCHEM MOL IPL INSECTICID DHARMAJ BHARATRAS ADVANCE HERANBAMcap ₹1,295 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	2.41
Current Ratio	0.95	1.00	0.93	0.89	0.89
Quick Ratio	0.39	0.51	0.50	0.61	0.61
Cash, Equiv & ST Investments	0.5	0.5	0.6	10.0	0.1
Working Capital	-27.3	1.3	-24.6	-56.8	-112.4

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.